Suppr超能文献

术后天冬氨酸转氨酶与淋巴细胞比率指数变化是小肝细胞癌患者生存的独立预测指标。

Postoperative aspartate aminotransferase to lymphocyte ratio index change is an independent predictor of survival in patients with small hepatocellular carcinoma.

作者信息

He Chao, Peng Wei, Li Chuan, Wen Tian-Fu

机构信息

Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China.

出版信息

Medicine (Baltimore). 2017 Nov;96(45):e8540. doi: 10.1097/MD.0000000000008540.

Abstract

Elevated preoperative aspartate aminotransferase (AST) to lymphocyte ratio index (ALRI) is reported to be a prognostic factor for patients with hepatocellular carcinoma (HCC) after treatment. However, [DELTA] ALRI which represents the change from postoperative ALRI to preoperative ALRI change has received little attention. The present study was designed to evaluate the prognostic value of [DELTA] ALRI in small HCC patients after liver resection.A retrospective cohort study was performed to analyze 241 patients with small HCC who underwent liver resection. Patients were divided into Group A ([DELTA] ALRI < 0, n = 142) and group B ([DELTA] ALRI ≥ 0, n = 99) according to postoperative ALRI change. Clinical data, overall survival (OS), and recurrence-free survival (RFS) were compared between the 2 groups, and a multivariate analysis was used to identify prognostic factors.The 1, 3, and 5-year OS rates were 96.5%, 84.9%, and 70.8%, respectively, for group A, and 94.9%, 75.8%, and 59.7%, respectively for group B (P = .014). The corresponding 1, 3, and 5-year RFS rates were 78.2%, 54.6%, and 52.3%, respectively, for group A, and 62.6%, 40.1%, 24.5%, respectively, for group B (P < .001). The results of univariate and multivariate analysis indicated that [DELTA] ALRI was an independent prognostic factor for both RFS (P < .001, hazard ratio [HR] 2.192, 95% confidence interval 1.527-3.147) and OS (P < .001, HR 2.381, 95% confidence interval 1.503-3.771).A positive [DELTA] ALRI after liver resection predicts decreased OS and RFS in patients with small HCC.

摘要

据报道,术前天冬氨酸转氨酶(AST)与淋巴细胞比率指数(ALRI)升高是肝细胞癌(HCC)患者治疗后的一个预后因素。然而,代表术后ALRI相对于术前ALRI变化的ΔALRI很少受到关注。本研究旨在评估ΔALRI在小肝癌患者肝切除术后的预后价值。

进行了一项回顾性队列研究,分析了241例行肝切除的小肝癌患者。根据术后ALRI变化将患者分为A组(ΔALRI < 0,n = 142)和B组(ΔALRI≥0,n = 99)。比较两组的临床资料、总生存期(OS)和无复发生存期(RFS),并采用多因素分析确定预后因素。

A组1、3和5年总生存率分别为96.5%、84.9%和70.8%,B组分别为94.9%、75.8%和59.7%(P = 0.014)。A组相应的1、3和5年无复发生存率分别为78.2%、54.6%和52.3%,B组分别为62.6%、40.1%、24.5%(P < 0.001)。单因素和多因素分析结果表明,ΔALRI是RFS(P < 0.001,风险比[HR] 2.192,95%置信区间1.527 - 3.147)和OS(P < 0.001,HR 2.381,95%置信区间1.503 - 3.771)的独立预后因素。

肝切除术后ΔALRI为阳性预示小肝癌患者的OS和RFS降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/645b/5690755/523a40c01c14/medi-96-e8540-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验